Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 775,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,205.18 pence per share.
- Total Cost: The filing text does not explicitly state the total aggregate cost of the transaction.
Material Changes
Following the repurchase and subsequent cancellation of the 775,000 shares, the company's capital structure was updated as follows:
- Treasury Shares: The company now holds 474,194,158 shares in Treasury, representing 9.09% of total voting rights.
- Shares in Issue: There are 5,218,693,637 shares in issue (excluding Treasury shares), which represents the total voting rights in the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total aggregate cost of the 775,000 share repurchase (not explicitly stated in the text).
- Confirm the updated total voting rights denominator (5,218,693,637 shares) for disclosure threshold calculations.
- Review the Treasury share percentage (9.09%) to assess its impact on future capital management or buyback programs.